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Abstract
Background: Research on the uptake and transport of astaxanthin is lacking in most species. We studied the uptake of 
astaxanthin by plasma, lipoproteins and leukocytes in domestic dogs and cats.
Methods: Mature female Beagle dogs (18 to 19 mo old; 11 to 14 kg BW) were dosed orally with 0, 0.1, 0.5, 2.5, 10 or 40 
mg astaxanthin and blood taken at 0, 3, 6, 9, 12, 18 and 24 h post-administration (n = 8/treatment). Similarly, mature 
domestic short hair cats (12 mo old; 3 to 3.5 kg body weight) were fed a single dose of 0, 0.02, 0.08, 0.4, 2, 5, or 10 mg 
astaxanthin and blood taken (n = 8/treatment) at the same interval.
Results: Both dogs and cats showed similar biokinetic profiles. Maximal astaxanthin concentration in plasma was 
approximately 0.14 μmol/L in both species, and was observed at 6 h post-dosing. The plasma astaxanthin elimination 
half-life was 9 to 18 h. Astaxanthin was still detectable by 24 h in both species. In a subsequent study, dogs and cats 
were fed similar doses of astaxanthin daily for 15 to 16 d and astaxanthin uptake by plasma, lipoproteins, and 
leukocytes studied. In both species, plasma astaxanthin concentrations generally continued to increase through d 15 
or 16 of supplementation. The astaxanthin was mainly associated with high density lipoprotein (HDL). In blood 
leukocytes, approximately half of the total astaxanthin was found in the mitochondria, with significant amounts also 
associated with the microsomes and nuclei.
Conclusion: Dogs and cats absorb astaxanthin from the diet. In the blood, the astaxanthin is mainly associated with 
HDL, and is taken up by blood leukocytes, where it is distributed to all subcellular organelles. Certain aspects of the 
biokinetic uptake of astaxanthin in dogs and cats are similar to that in humans.
Introduction
Research has shown that carotenoids play important
roles in modulating immunity [1], reproduction [2], can-
cer [3], age-related macular degeneration, and atheroscle-
rosis [4]. However, these studies have focused mainly on
β-carotene, lutein and lycopene. Recent studies have sim-
ilarly shown that astaxanthin, a ketocarotenoid, possesses
important biological actions [1]. The antioxidant activity
of astaxanthin has been reported to be higher than that of
α-carotene, β-carotene and lutein [5,6] and α-tocopherol
[7]. Astaxanthin reduced oil-induced oxidative stress [8]
and lowered serum lipid peroxides and transaminase
activities [9] in fish. Both in vitro and in vivo studies have
shown that astaxanthin can enhance humoral [10] and
cell-mediated [11] immune responses, and inhibit cancer
[12,13], and suppress bacterial infection [14]. In spite of
these known functions of astaxanthin, little is known
concerning its uptake in most species. Our immediate
objective is to study the biokinetic uptake of astaxanthin
by blood, lipoproteins and leukocytes in dogs and cats;
our long-term objective is to study the action of dietary
astaxanthin in modulating immune health in these spe-
cies.
Materials and Methods
The comparative uptake of dietary astaxanthin in domes-
tic dogs and cats was studied. All studies were approved
by the Washington State University Institutional Animal
Care and Use Committee.
Dog study
Female Beagle dogs (18 to 19 mo old, 11 to 14 kg BW)
were fed a nutritionally-balanced diet (200 g/dog/d, The
Iams Co., Lewisburg, OH). The diet composition was as
follows (g/kg): 66.2 moisture, 262 protein, 74.5 ash, 160
fat, 14.8 Ca, 10.3 P, and 437.3 nitrogen-free extract. All
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Page 2 of 8dogs were housed in 2 × 2 m pens (2 dogs/pen) in a tem-
perature- (20 to 22°C) and light- (14 h light) controlled
facility. In experiment 1, dogs were given one oral dose of
0, 0.1, 0.5, 2.5, 10 or 40 mg astaxanthin (Carophyll pink,
8% beadlet, Hoffmann La-Roche, Paramus, NJ); astaxan-
thin was suspended in 5 ml of water and fed orally using a
feeding syringe. A preliminary study with 3 dogs was
used to determine sampling times. Blood was taken from
the jugular vein at 0, 3, 6, 9, 12, 18 and 24 h post-adminis-
tration (n = 8/treatment).
In experiment 2, astaxanthin uptake from repeated oral
doses was studied. Dogs (n = 8/treatment) were dosed
once daily at 0800 h for 16 consecutive days with 0, 0.1,
0.5, 2.5, 10 or 40 mg astaxanthin. On days 0, 1, 2, 4, 6, 8,
10, 13 and 16, blood was taken 6 h after dosing; this sam-
pling time was chosen because peak concentrations of
astaxanthin were observed 6 h post-dosing in experiment
1. Plasma was collected following centrifugation at 400 ×
g, and analyzed by high performance liquid chromatogra-
phy (HPLC). The resultant buffy coat interface following
centrifugation was collected and subjected to Percoll
(Histopaque-1077, Sigma-Aldrich, St. Louis, MO) cen-
trifugation [15], and lymphocyte number determined
(Coulter Electronics, Hialeah, FL). Cells were resus-
pended in PBS containing 30 g/L sodium ascorbate
(Sigma-Aldrich) as an antioxidant, and disrupted by soni-
cation (30 s). An aliquot of the lymphocyte homogenate
was extracted for HPLC analysis of astaxanthin in whole
lymphocytes. The remaining lymphocyte homogenate
was subjected to subcellular fractionation as previously
described [15]. Briefly, the homogenates were centrifuged
to obtain the nuclear (600 × g for 10 min at 4°C), mito-
chondrial (17,300 × g for 20 min at 4°C), microsomal
(102,000 × g for 60 min at 4°C) and cytosolic fractions. All
samples were stored at -80°C prior to HPLC analysis.
Lipoprotein Separation and Cholesterol Analysis
Serum obtained from dogs fed 0, 2 or 10 mg astaxanthin
was used to isolate lipoproteins by density gradient ultra-
centrifugation [15,16]. Briefly, solid KBr (0.114 g) and
sucrose (0.025 g), serum (1 mL) and Sudan black (2.19
mol/L in ethylene glycol; Sigma-Aldrich) were placed in a
polycarbonate centrifuge tube and subsequently over-
layed with 2.4 mL salt solution (0.195 mol/L NaCl, 0.638
mol/L KBr, and 0.2 mmol/L disodium EDTA; density 1.06
g/mL), and then with 2.4 mL of 0.2 mmol/L disodium
EDTA in distilled water. The mixture was then centri-
fuged at 232,000 × g for 7 h at 20°C (Sorvall T-865.1 fixed
angle rotor, Sorvall OTD65B). The lipoprotein fractions
were removed and used for HPLC analysis of astaxanthin
and for cholesterol determination [15].
Cholesterol Analysis
Cholesterol reagent was prepared by first dissolving 520
mg ferric perchlorate in 600 mL ethyl acetate, cooled and
then adding 400 mL cold concentrated sulfuric acid. The
cholesterol reagent (25 mL) was added to 25 μL of sample
or standard (2 mg cholesterol/L in glacial acetic acid),
reacted for 1.5 min in a 100°C water bath before being
cooled to <20°C. Optical density was read at 600 nm.
Cat study
Mature female domestic short hair cats (12 mo of age; 3
to 3.5 kg body weight; Liberty Research, Waverly, NY)
were fed a basal diet (The Iams Co.) containing (g/kg): 72
moisture, 310 protein, 52 ash, 217 fat, 14 crude fiber, 11.5
Ca, 8.3 P. Cats were group-housed indoors in light- (14 h
light, 10 h dark) and temperature-controlled (20 - 22°C)
rooms. Two to three cats were housed in each 2 × 2 m
pen and had free access to food and water. In experiment
3, cats (n = 8/treatment) were given a single oral dose of
0, 0.02, 0.08, 0.4, 2, 5, or 10 mg astaxanthin; the astaxan-
thin was suspended in 1 mL of water and fed with a
syringe. Sampling times were chosen based on a prelimi-
nary study using three cats from which blood was sam-
pled at close intervals; blood was sampled from the
jugular vein at 0, 3, 6, 9, 12, 18 and 24 h after dosing. The
same oral doses of astaxanthin as above were adminis-
tered daily at 0800 h for 15 consecutive days (n = 8/treat-
ment; experiment 4). Blood was sampled once daily 6 h
after each feeding based on experiment 3 peak blood
astaxanthin concentrations. Plasma was separated for
HPLC analysis. In addition, a larger volume of blood was
taken on d 0, 6 and 15 for studying astaxanthin uptake by
blood leukocytes. Due to the inconsistency in obtaining a
reasonably pure population of lymphocytes, total blood
leukocytes were used for subcellular fractionation as
described earlier. On d 6 and 15, serum obtained from
cats fed 0, 2 or 10 mg astaxanthin was used to isolate lipo-
proteins fractions and cholesterol as described earlier.
HPLC Analysis
In both studies, plasma, lymphocyte homogenate and
lymphocyte subcellular fractions were analyzed for astax-
anthin content by HPLC (Alliance 2690 Waters HPLC
system fitted with a photodiode array detector, Waters,
Milford, MA) as previously described [17]. Protein in the
samples were first precipitated with an equal volume of
absolute ethanol containing BHT (1 g/L) before being
extracted using at least 6 volumes of a 1:1 mixture (v/v) of
petroleum ether:anhydrous diethyl ether. Extraction was
repeated until the pellet was clear and the solvent pooled
and dried under nitrogen gas. Trans-β-apo-8'carotenal
(Sigma Chem. Co., St. Louis, MO) was used as the inter-
nal standard. The mobile phase used was a mixture of
acetonitrile:methanol:water (47:47:16, v/v/v), and sam-
ples were eluted through a 5-μm spherical C-18 column
(3.9 × 150 mm Resolve, Waters, Milford, MA) with a flow
rate of 1.5 mL/min. Absorbance was monitored at 492
nm on a photodiode array detector.
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Page 3 of 8Statistical Analysis
Data were analyzed by repeated sampling analysis of vari-
ance using the General Linear Models of SAS. The statis-
tical model was Yijk = μ + Treatmenti +
Animalj(Treatmenti) (error A used to test the effects of
treatment) + Sampling periodk + Treatmenti*Periodk +
eijk (error B). Differences among treatment means within




Astaxanthin was undetectable in the plasma of all dogs
prior to astaxanthin supplementation, and also in unsup-
plemented dogs during the entire study period (Figure 1).
In contrast, plasma astaxanthin increased (P < 0.01) rap-
idly in a dose-dependent manner by 3 h post-dosing.
Plasma astaxanthin was low (0.002 μmol/L average) in
dogs fed 0.1 or 0.5 mg astaxanthin. Peak plasma concen-
trations were generally observed around 6 h after a single
oral dose. Dogs fed 40 mg astaxanthin had peak plasma
astaxanthin concentrations that were 4 and 11 times
higher than those fed 10 or 2.5 mg astaxanthin, respec-
tively, indicating a disproportionately greater increase in
plasma astaxanthin concentration in dogs fed 40 mg
astaxanthin. Plasma astaxanthin generally started to
decrease by 9 h post-dosing. However, at 24 h after dos-
ing, astaxanthin concentrations were still higher in dogs
fed 2.5, 10 or 40 mg astaxanthin when compared to con-
trol dogs. Plasma astaxanthin concentrations decreased
(P < 0.01) rapidly in dogs fed 40 mg astaxanthin but much
more gradually in those fed lower doses. The half-life of
astaxanthin in the plasma was approximately 9 h (40 mg)
to 18 h (0.5 to 10 mg groups). Astaxanthin feeding did not
influence plasma α-tocopherol and retinol concentra-
tions which averaged 9.3 ± 1.8 and 5.0 ± 0.4 μmol/L,
respectively.
When dogs were given daily doses of astaxanthin,
plasma concentrations of astaxanthin increased (P < 0.01)
dose-dependently (Figure 2). Concentrations increased (P
< 0.01) rapidly after the first dose and continued to
increase through d 16. In dogs fed 40 mg astaxanthin,
plasma astaxanthin averaged 4 and 9 times higher (P <
0.05) compared to those fed 10 and 2.5 mg astaxanthin.
Again, dietary astaxanthin did not influence plasma α-
tocopherol and retinol concentrations and averaged 8.9 ±
0.6 and 5.0 ± 0.3 μmol/L, respectively.
Astaxanthin in the blood was mainly associated with
the HDL fraction, with no detectable amounts in the LDL
and VLDL fractions. Uptake of astaxanthin by HDL was
dose-dependent (P < 0.05) and was maximal by d 6 in
dogs fed 10 or 40 mg astaxanthin (averaged 2.2 ± 0.4 and
3.2 ± 0.3 nmol/mg cholesterol, or 57.2 ± 3.9 and 97.9 ±
11.8 nmol/L plasma, respectively). Astaxanthin was not
detectable in any lipoprotein fraction in unsupplemented
dogs.
Astaxanthin was not detectable in whole lymphocyte
homogenates in control dogs and those fed 0.1 or 0.5 mg
astaxanthin for up to 16 d (Table 1). However, astaxan-
thin was measurable in whole lymphocytes on d 4, 8 or 16
in dogs fed 40, 10 or 2.5 mg astaxanthin, respectively, and
astaxanthin uptake was dose-related. Astaxanthin contin-
Figure 1 Concentrations of plasma astaxanthin in dogs (body 
weight = 11 to 14 kg) given a single oral dose of 0, 0.1, 0.5, 2.5, 10 
or 40 mg astaxanthin. Values are means ± SEM (n = 8) as analyzed by 
repeated measures ANOVA. Means with different superscripts within a 
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Figure 2 Concentrations of plasma astaxanthin in dogs (body 
weight = 11 to 14 kg) administered daily doses of 0, 0.1, 0.5, 2.5, 
10 or 40 mg astaxanthin orally. Values are means ± SEM (n = 8) as an-
alyzed by repeated measures ANOVA. Means with different super-
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Page 4 of 8ued to be accumulated by circulating lymphocytes
through d 16 of supplementation.
Fractionation of the peripheral blood lymphocytes
revealed that the initial subcellular uptake of astaxanthin
was by microsomes and nuclei, with approximately equal
distribution between these two fractions (Table 1). Again,
astaxanthin was measurable starting on d 4, 8 and 16 in
dogs fed 40, 10 or 2.5 mg astaxanthin, respectively. By the
next sampling period (d 8 for 40 mg group or d 16 for the
10 mg group), astaxanthin uptake was highest in the
mitochondria (35 to 50% of total astaxanthin in lympho-
cytes), followed by the microsomes (26 to 30% of total
astaxanthin taken up). During this latter period, the
nuclei still contained a significant portion (16 to 18%) of
total astaxanthin in the lymphocytes.
Uptake in Cats
Uptake of dietary astaxanthin in cat plasma after a single
dose was dose-dependent (Figure 3). As with dogs, astax-
anthin was not detectable in unsupplemented cats. Peak
plasma concentrations were generally observed between
3 to 6 h. Whereas plasma astaxanthin concentrations in
cats fed 2 to 10 mg astaxanthin generally reflected dietary
doses, concentrations in cats fed 0.4 mg astaxanthin or
less were much lower. In fact, astaxanthin was not detect-
able in the plasma of cats fed 0.02 or 0.08 mg astaxanthin.
At 24 h after dosing, plasma astaxanthin was still higher
in cats fed 5 or 10 mg astaxanthin when compared to
control cats. The plasma astaxanthin elimination half-life
was approximately 6 h.
Table 1: Uptake and relative distribution percentages of astaxanthin in whole leukocytes and subcellular fractions in dogs 
fed 0, 0.1, 0.5, 2.5, 10 or 40 mg astaxanthin daily for 15d
Treatment (mg astaxanthin/dog/d)
0 0.1 0.5 2.5 10 40
Day 4
Whole leukocyte (nmol astaxanthin/108 cells)
nd nd nd nd nd 6.8 ± 1.7*
Subcellular fraction (% of whole leukocyte)
Nuclei nd nd nd nd nd 49
Mitochondria nd nd nd nd nd nd
Microsome nd nd nd nd nd 51
Cytosol nd nd nd nd nd nd
Day 8
Whole leukocyte (nmol astaxanthin/108 cells)
nd nd nd nd 7.1 ± 1.6* 50.6 ± 11.7*
Subcellular fraction (% of whole leukocyte)
Nuclei nd nd nd nd 49 18
Mitochondria nd nd nd nd nd 50
Microsome nd nd nd nd 51 26
Cytosol nd nd nd nd nd 6
Day 16
Whole leukocyte (nmol astaxanthin/108 cells)
nd nd nd 2.5 ± 0.6* 21.8 ± 5.1* 66.4 ± 15.4*
Subcellular fraction (% of whole leukocyte)
Nuclei nd nd nd 45 16 22
Mitochondria nd nd nd nd 35 43
Microsome nd nd nd 55 30 28
Cytosol nd nd nd nd 19 7
Total leukocyte values are means ± SEM (n = 8) as analyzed by repeated measures ANOVA.
*Means within a row are significantly different from unsupplemented animals (P < 0.05).
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Page 5 of 8Concentrations of plasma α-tocopherol and retinol
were not influenced by astaxanthin supplementation and
averaged 10.4 ± 0.7 and 0.61 ± 0.04 μmol/L, respectively.
Daily doses of astaxanthin administered for 15 d
resulted in a dose-dependent increase (P < 0.01) in
plasma concentrations of astaxanthin (Figure 4). Concen-
trations increased (P < 0.01) rapidly after the first dose
and continued to increase through d 15 in cats given 5 or
10 mg astaxanthin. Plasma astaxanthin concentrations in
cats given astaxanthin doses 0.08 or lower were generally
undetectable. Longer term feeding of astaxanthin did not
significantly alter concentrations of plasma α-tocopherol
and retinol (10.5 ± 0.1 and 0.60 ± 0.01 μmol/L, respec-
tively).
As observed in dogs, almost all astaxanthin in the blood
of cats was associated with the HDL fraction. Astaxan-
thin incorporation into HDL was dose-dependent (P <
0.05) and was maximal by d 6 in cats fed both 2 and 10
mg astaxanthin (averaged 5.4 ± 0.2 and 18.3 ± 2.6 pmol/
mg cholesterol, or 20.4 ± 0.1 and 73.4 ± 8.2 nmol/L
plasma, respectively). There was no further increase in
astaxanthin uptake on d 16, with astaxanthin concentra-
tions for cats fed 2 or 10 mg averaging 3.8 ± 0.65 and 13.3
± 0.4 pmol/mg cholesterol, or 15.6 ± 2.6 and 59.7 ± 2.6
nmol/L plasma, respectively. Astaxanthin was not detect-
able in any lipoprotein fraction from unsupplemented
cats.
Astaxanthin uptake in whole lymphocytes of cats
administered daily doses of astaxanthin increased dose-
dependently as measured on d 6 and 15 of the study
(Table 2). Daily dietary doses as low as 0.02 mg astaxan-
thin produced detectable uptake by lymphocytes on d 15.
The distribution of astaxanthin in the different subcel-
lular lymphocyte fractions were generally dose-related
(Table 2). With daily oral doses of 0.4 to 10 mg astaxan-
thin, there was significant uptake of astaxanthin by the
nuclei and mitochondria on d 6. On d 6, astaxanthin was
detectable in the microsomes and cytosol of cats fed
higher doses (5 and 10 mg). However, by d 15, all astaxan-
thin doses produced significant uptake of astaxanthin in
all subcellular fractions, including the microsomes.
Regardless of dietary doses, the greatest proportion of
astaxanthin seems to be associated with the mitochon-
dria, followed by the nuclei (Table 2).
Discussion
Interest in the biological activity of astaxanthin has
increased recently due to its role as an antioxidant [5], in
enhancing humoral [10] and cell-mediated [11] immune
responses, in inhibiting mammary [12] and bladder [13]
cancer growth, and in gene regulation [18]. As an antioxi-
dant, astaxanthin has been shown to possess relatively
higher activity as compared to α-carotene, β-carotene
and lutein [6]. In fact, the antioxidant activity of astaxan-
thin against certain kinds of reactive oxygen under sev-
eral experimental conditions has been observed to be
stronger than that of α-tocopherol [7].
Aside from a study of rainbow trout [19,20], little is
known concerning the uptake and metabolism of astax-
anthin. In this study, we showed that both domestic dogs
and cats absorbed astaxanthin when administered orally.
The maximum concentration of astaxanthin in plasma of
Figure 3 Concentrations of plasma astaxanthin in cats (body 
weight = 3.0 to 3.5 kg) given a single oral dose of 0, 0.02, 0.08, 0.4, 
2, 5, or 10 mg astaxanthin. Values are means ± SEM (n = 8) as ana-
lyzed by repeated measures ANOVA. Means with different superscripts 
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Figure 4 Concentrations of plasma astaxanthin in cats (body 
weight = 3.0 to 3.5 kg) administered daily doses of 0, 0.02, 0.08, 
0.4, 2, 5, or 10 mg astaxanthin. Values are means ± SEM (n = 8) as an-
alyzed by repeated measures ANOVA. Means with different super-
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Page 6 of 8both dogs and cats after a single dose of approximately
3.3 mg astaxanthin/kg body weight was similar in the two
species and averaged 0.14 μmol/L. Osterlie et al. [21]
reported that the maximum plasma astaxanthin concen-
tration in 3 human subjects given a single dose of 100 mg
astaxanthin (equivalent to approximately 1.1 mg astaxan-
thin/kg body weight) was 2.3 μmol/L. Therefore, the effi-
ciency of absorption of oral astaxanthin is higher in
humans than in domestic dogs and cats.
Peak concentrations of astaxanthin in plasma in both
species were observed 3 to 6 h postprandially in this
study, which is similar to that reported in humans [21],
but earlier than that reported with β-carotene in cats at
12 to 24 h [22], humans at 24 to 48 h [23,24], and preru-
minant calves at 12 h to 30 h [25]. However, peak plasma
β-carotene in dogs also was observed at 6 h after a single
dose [26].
Maximal concentrations of astaxanthin in dogs and cats
after a single dose were also lower than β-carotene in cats
[22], preruminant calves [25], and ferrets [27], but higher
than β-carotene uptake in dogs [26]. In contrast, mice
showed a 50 fold higher uptake of oral astaxanthin com-
pared to β-carotene [22,26,28,29] when fed higher
amounts of astaxanthin (0.02 to 0.4% of the diet). There-
fore, large species differences occur in the rate of absorp-
tion of different carotenoids.
In this study, plasma astaxanthin concentrations con-
tinued to increase in both dogs and cats to above 0.2
μmol/L after 15 or 16 d of astaxanthin administration,
even though the rate of increase was much lower after the
first day. Therefore, plasma saturation concentration for
astaxanthin in dogs and cats cannot be deduced from this
study. We [17] recently reported similar concentrations
(0.1 μmol/L) of plasma astaxanthin in 28 human subjects
given 2 to 8 mg astaxanthin daily for 8 wk. In the latter
study, plasma saturation was observed after 4 wk feeding.
Oral astaxanthin is generally more bioavailable in cats
than in dogs especially when compared across multiple
doses. This may be due to a lack of the 15,15 monoxyge-
nase (or other oxygenases) in cats, resulting in the
reduced cleavage of astaxanthin in the intestine. Alterna-
tively, the ad libitum feeding of cats may have resulted in
multiple spikes in astaxanthin absorption as opposed to
the consumption of two meals by the dogs.
Plasma astaxanthin elimination half-life was longer in
dogs (9 to 18 h) than in cats (6 h), and was still detectable
24 h after dosing. The elimination rate may be more rapid
in these species, since the half-life of 11 to 32 h reported
in humans is longer [21], and may partly explain the
Table 2: Uptake and relative distribution percentages of astaxanthin in whole leukocytes and subcellular fractions in cats 
fed 0, 0.02, 0.08, 0.4, 2, 5 or 10 mg astaxanthin daily for 15d
Treatment (mg astaxanthin/cat/d)
0 0.02 0.08 0.4 2 5 10
Day 6
Whole leukocyte (nmol astaxanthin/108 cells)
nd nd nd 52 ± 0* 222 ± 76* 339 ± 75* 687 ± 29*
Subcellular fraction (% of whole leukocyte)
Nuclei nd nd nd 40 40 28 23
Mitochondria nd nd nd 60 41 44 50
Microsome nd nd nd nd 19 14 14
Cytosol nd nd nd nd nd 14 13
Day 15
Whole leukocyte (nmol astaxanthin/108 cells)
nd 44 ± 0* 49 ± 0* 84 ± 3* 169 ± 33* 357 ± 56* 468 ± 36*
Subcellular fraction (% of whole leukocyte)
Nuclei nd nd nd 36 21 24 17
Mitochondria nd nd 39 33 40 45 49
Microsome nd 46 31 16 20 15 18
Cytosol nd 54 30 16 20 16 15
Total leukocyte values are means ± SEM (n = 8) as analyzed by repeated measures ANOVA.
*Means within a row are significantly different from unsupplemented animals (P < 0.05).
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elimination rate in dogs which showed undetectable
amounts 24 h after an individual dose [26] is more rapid
than in cats which had detectable levels at 72 h [22], fer-
rets at 75 h [27], preruminant calves at 240 h [25], and
humans at 120 h [30].
Carotenoids are absorbed in the intestinal mucosa and
then transported in the blood in association with plasma
lipoproteins [31]. Carotenoids associated with chylomi-
cra are transported via the lymph and blood to the liver
where they are partly re-secreted with lipoproteins. High
density lipoprotein is the major lipoprotein in the blood
of dogs and cats. In this study, astaxanthin in the blood
was present predominantly in HDL in both dogs and cats.
Maximal uptake by the HDL occurred by d 6 of feeding in
both species and was dose-related. In humans, most of
the astaxanthin was found in the VLDL chylomicra (36 to
64%), with lesser, equal amounts distributed between the
LDL and HDL [21]. The distribution of polar xan-
thophylls in lipoproteins is different from non-polar caro-
tenoids [32]. Whereas carotenes are mainly transported
in LDL, xanthophylls tend be found more equally distrib-
uted between HDL and LDL [33,34].
Examination of astaxanthin uptake by blood leukocytes
again revealed similarities between dogs and cats. The
mitochondria accounted for 40 to 50% of total astaxan-
thin taken up by blood leukocytes in both species while
the microsomes and nuclei also took up significant
amounts of astaxanthin. No reports are available on the
subcellular distribution of astaxanthin in blood leuko-
cytes from other species for the purpose of comparisons.
We have previously reported subcellular uptake of dietary
β-carotene in these and other species. Mitochondria
again accounted for 40 to 52% of total β-carotene uptake
by blood leukocytes in cats [22] and calves [15], but was
lower in dogs with only 14 to 17% [26]. Uptake of β-caro-
tene by blood leukocytes and leukocyte subcellular frac-
tions also has been reported in humans [35], and pigs
[36]. The presence of astaxanthin in the various subcellu-
lar organelles suggests the involvement of this antioxidant
in cellular function. The mitochondria, through their
electron transport system, utilize about 85% of the total
oxygen consumed by the cell, thereby producing large
quantities of reactive oxygen species [37]. Indeed,
changes in mitochondrial and plasma membrane poten-
tial can influence cell-mediated immune function [37].
Also, astaxanthin supplementation in vitamin E-deficient
rats protected mitochondria and erythrocyte ghosts from
Fe-catalyzed lipid peroxidation [38]. In vivo, astaxanthin
is located in membranes that contain a large amount of
polyunsaturated fatty acids [39], and is therefore strategi-
cally located to afford protection against lipid peroxida-
tion. Previous reports have shown that astaxanthin is
more effective than β-carotene in decreasing the rate of
formation of methyl linoleate hydroperoxides [40] and in
preventing lipid peroxidation in rat liver microsomes
[41]. Astaxanthin, in nanomolar concentrations, was able
to prevent paraquat-induced oxidative stress in chicken
embryo fibroblasts [42]; in the latter study, the activity of
astaxanthin surpassed that of α-tocopherol and β-caro-
tene. The high antioxidant activity of astaxanthin is
attributed to the presence of a keto- and OH- group in
each ionone ring which allows the molecule to be esteri-
fied, and makes it more polar than other carotenoids.
Xanthophylls are thought to be located in the cell mem-
brane lipid bilayer with their hydrophobic groups in the
aqueous phase or anchored in the polar head region of
the lipid bilayer [43]; this increases membrane rigidity
and allows them to serve as molecular rivets to impair the
entry of small polar molecules such as singlet oxygen.
The stereoisomer form of astaxanthin was not identi-
fied in this study. However, there is a preferential uptake
of the Z-isomers as compared to the all-E-astaxanthin in
humans [21]. The source of astaxanthin in this study is
Haematococcus pluvialis; astaxanthin exists primarily as
a monoester and in the form of the 3S,3'S enantiomer.
Synthetic astaxanthin [21], on the other hand, contains
primarily the 3R,3'S form.
In summary, domestic dogs and cats fed astaxanthin
generally showed different biokinetic profiles when com-
pared to humans and other species. Whether astaxanthin
supplementation can modulate immune and anti-inflam-
matory/antioxidative function remains to be elucidated.
However, this study provides target dietary doses to use
in functional studies in dogs and cats.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JSP and BPC designed research, analyzed data, and wrote the paper; JSP, BPC,
BDM, HWK conducted research; MGH, SM, GAR provided essential materials;
BPC had primary responsibility for final content. All authors read and approved
the final manuscript.
Acknowledgements
This work was supported by a grant from P&G Pet Care, Lewisburg, OH and the 
Agricultural Research Station, College of Agriculture and Home Economics, 
Washington State University, Pullman, WA.
Author Details
1School of Food Science, Washington State University, Pullman, WA 99164-
6376, USA and 2P&G Pet Care, Lewisburg, OH 45338, USA
References
1. Chew BP, Park JS: Carotenoids Against Disease: Part C. The Immune 
System and Disease.  In Carotenoids: Nutrition and Health Volume 5. Edited 
by: Britton G, Liaanen-Jensen S, Pfander H. Germany: Birkhauser Press; 
2009:363-382. 
2. Chew BP: The influence of vitamins on reproduction in pigs.  In Recent 
Advances in Animal Nutrition Edited by: Garnsworthy PC, Cole DJA. 
England: Nottingham Univ. Press; 1995:223-239. 
Received: 7 January 2010 Accepted: 21 June 2010 
Published: 21 June 2010
This article is available from: http://www.nutritionandmetabolism.com/content/7/1/52© 2010 Park et al; licensee BioMed Central L d. is an Op n Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Nutritio  & Met bolism 2010, 7:52
Park et al. Nutrition & Metabolism 2010, 7:52
http://www.nutritionandmetabolism.com/content/7/1/52
Page 8 of 83. Weisburger JH: Nutritional approach to cancer prevention with 
emphasis on vitamins, antioxidants and carotenoids.  Am J Clin Nutr 
1991, 53:226S-237S.
4. Esterbauer H, Striegl G, Puhl H, Oberreither S, Rotheneder M, El-Saadani M, 
Jurgens G: The role of vitamin E and carotenoids in preventing 
oxidation of low density lipoproteins.  Ann N Y Acad Sci 1989, 
570:254-267.
5. Martin HD, Jager C, Ruck C, Schmidt M, Walsh R, Paust J: Anti- and 
prooxidant properties of carotenoids.  J Prakt Chem 1999, 341:302-308.
6. Naguib YM: Antioxidant activities of astaxanthin and related 
carotenoids.  J Agric Food Chem 2000, 48:1150-1154.
7. Miki W: Biological functions and activities of animal carotenoids.  Pure 
Appl Chem 1991, 63:141-146.
8. Nakano T, Kanmuri T, Sato M, Takeuchi M: Effect of astaxanthin rich red 
yeast (Phaffia rhodozyma) on oxidative stress in rainbow trout.  
Biochim Biophys Acta 1999, 1426:119-125.
9. Nakano T, Tosa M, Takeuchi M: Improvement of biochemical features in 
fish health by red yeast and synthetic astaxanthin.  J Agric Food Chem 
1995, 43:1570-1573.
10. Jyonouchi H, Sun S, Tomita Y, Gross MD: Astaxanthin, a carotenoid 
without vitamin A activity, augments antibody responses in cultures 
including T-helper cell clones and suboptimal doses of antigen.  J Nutr 
1995, 125:2483-2492.
11. Chew BP, Wong MW, Park JS, Wong TS: Dietary beta-carotene and 
astaxanthin but not canthaxanthin stimulate splenocyte function in 
mice.  Anticancer Res 1999, 19:5223-5227.
12. Chew BP, Park JS, Wong MW, Wong TS: A comparison of the anticancer 
activities of dietary beta-carotene, canthaxanthin and astaxanthin in 
mice in vivo.  Anticancer Res 1999, 19:1849-1853.
13. Tanaka T, Morishita Y, Suzui M, Kojima T, Okumura A, Mori H: 
Chemoprevention of mouse urinary bladder carcinogenesis by the 
naturally occurring carotenoid astaxanthin.  Carcinogenesis 1994, 
15:15-19.
14. Bennedsen M, Wang X, Willen R, Wadstrom T, Andersen LP: Treatment of 
H. pylori infected mice with antioxidant astaxanthin reduces gastric 
inflammation, bacterial load and modulates cytokine release by 
splenocytes.  Immunol Lett 1999, 70:185-189.
15. Chew BP, Wong TS, Michal JJ: Uptake of orally administered beta-
carotene by blood plasma, leukocytes, and lipoproteins in calves.  J 
Anim Sci 1993, 71:730-739.
16. Terpstra AH, Woodward CJ, Sanchez-Muniz FJ: Improved techniques for 
the separation of serum lipoproteins by density gradient 
ultracentrifugation: visualization by prestaining and rapid separation 
of serum lipoproteins from small volumes of serum.  Anal Biochem 
1981, 111:149-157.
17. Park J, Chyun JH, Kim YK, Line LL, Chew BP: Astaxanthin decreased 
oxidative stress and inflammation and enhanced immune response in 
humans.  Nutr Metab 2010, 7:18-27.
18. Bertram J: Carotenoids and gene regulation.  Nutr Rev 1999, 57:182-191.
19. Bjerkeng B, Folling M, Lagocki S, Storebakken T, Olli JJ, Alsted N: 
Bioavailability of all-E-astaxanthin and Z-isomers of astaxanthin in 
rainbow trout (Oncorhynchus mykiss).  Aquaculture 1997, 157:63-82.
20. Osterlie M, Bjerkeng B, Liaaen-Jensen S: Accumulation of astaxanthin all-
E, 9Z and 13Z geometrical isomers and 3 and 3' RS optical isomers in 
rainbow trout (Oncorhynchus mykiss) is selective.  J Nutr 1999, 
129:391-398.
21. Osterlie M, Bjerkeng B, Liaaen-Jensen S: Plasma appearance and 
distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins 
of men after single dose administration of astaxanthin.  J Nutr Biochem 
2000, 11:482-490.
22. Chew BP, Park JS, Weng BC, Wong TS, Hayek MG, Reinhart GA: Dietary 
beta-carotene absorption by blood plasma and leukocytes in domestic 
cats.  J Nutr 2000, 130:2322-2325.
23. Cornwell DG, Kruger FA, Robinson HB: Studies on the absorption of beta-
carotene and the distribution of total carotenoids in human serum 
lipoprotein after oral administration.  J Lipid Res 1962, 3:65-70.
24. Brown ED, Micozzi MS, Craft NE, Bieri JG, Beecher G, Edwards BK, Rose A, 
Taylor PR, Smith JC Jr: Plasma carotenoids in normal men after a single 
ingestion of vegetables or purified beta-carotene.  Am J Clin Nutr 1989, 
49:1258-1265.
25. Poor CL, Bierer TL, Merchen NR, Fahey GC Jr, Murphy MR, Erdman JW Jr: 
Evaluation of the preruminant calf as a model for the study of human 
carotenoid metabolism.  J Nutr 1992, 122:262-268.
26. Chew BP, Park JS, Weng BC, Wong TS, Hayek MG, Reinhart GA: Dietary 
beta-carotene is taken up by blood plasma and leukocytes in dogs.  J 
Nutr 2000, 130:1788-1791.
27. Gugger ET, Bierer TL, Henze TM, White WS, Erdman JW Jr: Beta-carotene 
uptake and tissue distribution in ferrets (Mustela putorius furo).  J Nutr 
1992, 122:115-119.
28. Park JS, Chew BP, Wong TS, Zhang JX, Magnuson NS: Dietary lutein but 
not astaxanthin or beta-carotene increases pim-1 gene expression in 
murine lymphocytes.  Nutr Cancer 1999, 33:206-212.
29. Park JS, Chew BP, Hayek MG, Massimino S, Reinhart GA: Dietary beta-
carotene enhances cell-mediated and humoral immune response in 
cats.  FASEB J 2004, 18:A533.
30. Schwedhelm E, Maas R, Troost R, Boger RH: Clinical pharmacokinetics of 
antioxidants and their impact on systemic oxidative stress.  Clin 
Pharmacokinet 2003, 42:437-459.
31. Olson JA: Absorption, metabolism, and transport of carotenoids in 
humans.  Pure Appl Chem 1994, 66:1011-1016.
32. Romanchik JE, Morel DW, Harrison EH: Distributions of carotenoids and 
alpha-tocopherol among lipoproteins do not change when human 
plasma is incubated in vitro.  J Nutr 1995, 125:2610-2617.
33. Krinsky NI, Cronwell DG, Oncley JL: The transport of vitamin A and 
carotenoids in human plasma.  Arch Biochem Biophys 1958, 73:233-246.
34. Goulinet S, Chapman MJ: Plasma LDL and HDL subspecies are 
heterogenous in particle content of tocopherols and oxygenated and 
hydrocarbon carotenoids.  Arterioscler Thromb Vasc Biol 1997, 17:786-796.
35. Mathews-Roth MM: Carotenoids in the leukocytes of carotenemic and 
non-carotenemic individuals.  Clin Chem 1978, 24:700-701.
36. Chew BP, Wong TS, Michal JJ, Standaert FE, Heirman LR: Subcellular 
distribution of beta-carotene, retinol and alpha-tocopherol in porcine 
lymphocytes after a single injection of beta-carotene.  J Anim Sci 1991, 
69:4892-4897.
37. Shigenaga MK, Hagen TM, Ames BN: Oxidative damage and 
mitochondrial decay in aging.  Proc Natl Acad Sci 1994, 91:10771-10778.
38. Kurashige M, Okimasu E, Inoue M, Utsumi K: Inhibition of oxidative injury 
of biological membranes by astaxanthin.  Physiol Chem Phys Med NMR 
1990, 22:27-38.
39. Britton G: Structure and properties of carotenoids in relation to 
function.  FASEB J 1995, 9:1551-1558.
40. Terao J: Antioxidant activity of beta-carotene-related carotenoids in 
solution.  Lipids 1989, 24:659-661.
41. Palozza P, Krinsky NI: Astaxanthin and canthaxanthin are potent 
antioxidants in a membrane model.  Arch Biochem Biophys 1992, 
297:291-295.
42. Lawlor SM, O'Brien NM: Astaxanthin: antioxidant effects in chicken 
embryo fibroblasts.  Nutr Res 1995, 15:1695-1704.
43. Griszecki WI, Sujak A, Strzalka K, Radunz A, Schmid GH: Organisation of 
xanthophylls-lipid membranes studied by means of specific pigment 
antisera, spectrophotometry and monomolecular layer technique 
lutein versus zeaxanthin.  Z Naturforsch C 1999, 54:517-525.
doi: 10.1186/1743-7075-7-52
Cite this article as: Park et al., Astaxanthin uptake in domestic dogs and cats 
Nutrition & Metabolism 2010, 7:52
